Volume 74, Issue Supplement_3, April 2019

Preface

• Extract
• View article

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin

• Abstract
• View article

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

• Abstract
• View article

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

• Abstract
• View article

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing

• Abstract
• View article

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

• Abstract
• View article

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

• Abstract
• View article
• Supplementary data